阿司匹林通过抑制血小板活性来抑制肝细胞癌的进展
Li-Jun Zhao1,2, Zhi-Yin Wang1, Wei-Ting Liu2
1Hematology Laboratory, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, Henan Province, China.
阿司匹林通过阻断血小板 (PLT) 激活来抑制肝细胞癌 (HCC) 的进展. 这项研究揭示了血小板促进HCC生长和转移,这表明抗血小板治疗是肝癌的有希望的治疗策略.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞癌 (HCC) 是一种普遍存在的肝脏恶性瘤.
- 血小板 (PLTs) 涉及肝脏平衡和疾病病理学.
- 血小板和阿司匹林对HCC进展的确切作用需要阐明.
研究的目的:
- 研究阿司匹林抗血小板作用对肝细胞癌 (HCC) 发展的影响.
- 了解血小板影响HCC进展的分子机制.
主要方法:
- 血小板和HCC细胞的共同培养,随后对生长,转移和炎症标志物的分析.
- 使用RT-PCR和西方涂抹检测与瘤相关的信号通路.
- 在体外和体内评估阿司匹林对血小板激活和HCC进展的影响.
主要成果:
- 血小板显著增强HCC细胞的生长,入侵,上皮-介质细胞过渡,并创造一个炎症微环境.
- 活性血小板通过MAPK/AKT/STAT3信号通路促进HCC.
- 阿司匹林有效地抑制了血小板激活,从而抑制了HCC在体外和体外的进展.
结论:
- 血小板在HCC的发病过程中起着至关重要的作用.
- 阿司匹林通过抑制HCC中的血小板活性来发挥抗瘤作用.
- 抗血小板疗法为HCC治疗和组合疗法提供了一个有希望的途径.
更多相关视频
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
